Patricia de la Riva1, Kara Smith2, Sharon X Xie2, Daniel Weintraub2. 1. From the Department of Neurology (P.d.l.R.), University Hospital Donostia, San Sebastián, Spain; Department of Biostatistics and Epidemiology (S.X.X.) and Departments of Neurology and Psychiatry (D.W.), Perelman School of Medicine at the University of Pennsylvania (K.S.), Philadelphia; and Department of Veterans Affairs (D.W.), Philadelphia VA Medical Center. patricia.delariva@gmail.com. 2. From the Department of Neurology (P.d.l.R.), University Hospital Donostia, San Sebastián, Spain; Department of Biostatistics and Epidemiology (S.X.X.) and Departments of Neurology and Psychiatry (D.W.), Perelman School of Medicine at the University of Pennsylvania (K.S.), Philadelphia; and Department of Veterans Affairs (D.W.), Philadelphia VA Medical Center.
Abstract
OBJECTIVE: To evaluate the course and predictors of neuropsychiatric symptoms (NPS) and cognition in patients with de novo Parkinson disease (PD). METHODS: Cross-sectional study of the cohort of de novo, untreated (at enrollment) patients with PD and healthy controls (HCs) from the Parkinson's Progression Markers Initiative. Participants have serial assessments of global cognition and symptoms of depression, anxiety, psychosis, impulse control disorders (ICDs), sleep and wakefulness, apathy, and fatigue. Available data up to 24 months of follow-up were included. RESULTS: The available sample size was as follows: baseline (PD = 423, HCs = 196), 12 months (PD = 261, HCs = 145), and 24 months (PD = 96, HCs = 83). Patients with PD experienced more depression, fatigue, apathy, and anxiety than HCs at all time points, and apathy (p = 0.001) and psychosis (p = 0.003) increased over time in patients with PD. Approximately two-thirds of patients with PD who screened positive for depression at any given visit were not taking an antidepressant. The Montreal Cognitive Assessment score decreased significantly over time in patients with PD (p < 0.001), but the change was comparable to that in HCs. At the 24-month visit, 44% of patients had been on dopamine replacement therapy (DRT) for at least 1 year, and this group reported more incident ICDs (p = 0.009) and excessive daytime sleepiness (p = 0.03). CONCLUSION: Multiple NPS are more common in de novo, untreated patients with PD compared with the general population, but they also remain relatively stable in early disease, while global cognition slightly deteriorates. In contrast, initiation of DRT is associated with increasing frequency of several other NPS.
OBJECTIVE: To evaluate the course and predictors of neuropsychiatric symptoms (NPS) and cognition in patients with de novo Parkinson disease (PD). METHODS: Cross-sectional study of the cohort of de novo, untreated (at enrollment) patients with PD and healthy controls (HCs) from the Parkinson's Progression Markers Initiative. Participants have serial assessments of global cognition and symptoms of depression, anxiety, psychosis, impulse control disorders (ICDs), sleep and wakefulness, apathy, and fatigue. Available data up to 24 months of follow-up were included. RESULTS: The available sample size was as follows: baseline (PD = 423, HCs = 196), 12 months (PD = 261, HCs = 145), and 24 months (PD = 96, HCs = 83). Patients with PD experienced more depression, fatigue, apathy, and anxiety than HCs at all time points, and apathy (p = 0.001) and psychosis (p = 0.003) increased over time in patients with PD. Approximately two-thirds of patients with PD who screened positive for depression at any given visit were not taking an antidepressant. The Montreal Cognitive Assessment score decreased significantly over time in patients with PD (p < 0.001), but the change was comparable to that in HCs. At the 24-month visit, 44% of patients had been on dopamine replacement therapy (DRT) for at least 1 year, and this group reported more incident ICDs (p = 0.009) and excessive daytime sleepiness (p = 0.03). CONCLUSION: Multiple NPS are more common in de novo, untreated patients with PD compared with the general population, but they also remain relatively stable in early disease, while global cognition slightly deteriorates. In contrast, initiation of DRT is associated with increasing frequency of several other NPS.
Authors: Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub Journal: Lancet Neurol Date: 2010-05-07 Impact factor: 44.182
Authors: Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang Journal: Arch Neurol Date: 2010-05
Authors: D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre Journal: Neurology Date: 2010-09-21 Impact factor: 9.910
Authors: D Aarsland; K Brønnick; G Alves; O B Tysnes; K F Pedersen; U Ehrt; J P Larsen Journal: J Neurol Neurosurg Psychiatry Date: 2009-08 Impact factor: 10.154
Authors: Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon Journal: Mov Disord Date: 2009-07-30 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Benzi M Kluger; Karen Herlofson; Kelvin L Chou; Jau-Shin Lou; Christopher G Goetz; Anthony E Lang; Daniel Weintraub; Joseph Friedman Journal: Mov Disord Date: 2016-02-16 Impact factor: 10.338
Authors: Sonja Rutten; Peter M van der Ven; Daniel Weintraub; Gregory M Pontone; Albert F G Leentjens; Henk W Berendse; Ysbrand D van der Werf; Odile A van den Heuvel Journal: Parkinsonism Relat Disord Date: 2017-07-05 Impact factor: 4.891
Authors: Paolo Calabresi; Veronica Ghiglieri; Petra Mazzocchetti; Ilenia Corbelli; Barbara Picconi Journal: Philos Trans R Soc Lond B Biol Sci Date: 2015-07-05 Impact factor: 6.237
Authors: Elizabeth L Birchall; Harrison C Walker; Gary Cutter; Stephanie Guthrie; Allen Joop; Raima A Memon; Ray L Watts; David G Standaert; Amy W Amara Journal: Brain Stimul Date: 2016-12-27 Impact factor: 8.955
Authors: L M Chahine; S X Xie; T Simuni; B Tran; R Postuma; A Amara; W H Oertel; A Iranzo; C Scordia; M Fullard; C Linder; R Purri; A Darin; L Rennert; A Videnovic; P Del Riva; D Weintraub Journal: Parkinsonism Relat Disord Date: 2016-03-12 Impact factor: 4.891